Arrowhead Pharmaceuticals Provides Update on Heparc-2004 Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Arrowhead Research (ARWR) PT Lowered to $5 at Jefferies Following Clinical Hold
November 10, 2016 7:54 AM ESTJefferies analyst Eun Yang reiterated a Hold rating and cut his price target on Arrowhead Research (NASDAQ: ARWR) to $5.00 (from $6.50) following clinical hold.
Yang commented, "FDA's decision to place a clinical hold on Heparc-2004 trial of ARC-520 based on death in... More
